Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin
Status: | Completed |
---|---|
Conditions: | Cancer, Brain Cancer, Cardiology, Endocrine |
Therapuetic Areas: | Cardiology / Vascular Diseases, Endocrinology, Oncology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 4/21/2016 |
Start Date: | September 2009 |
End Date: | June 2015 |
An Open Label, Multicenter, Single Arm Study of Pasireotide LAR in Patients With Rate Tumors of Neuroendocrine Origin
This study will assess the effectiveness and safety of pasireotide long-acting release in
patients who have rare tumors of neuroendocrine origin.
patients who have rare tumors of neuroendocrine origin.
Inclusion Criteria:
- Male and Female Patients at least 18 years old
- Patient who have rare tumors of neuroendocrine origin, such as tumors of the:
1. pancreas
2. pituitary glands
3. Nelson syndrome
4. ectopic-ACTH secreting tumor
- Patients who have failed standard of care treatment or for whom no standard of care
treatment exist
- Signed Informed Consent
Exclusion Criteria:
- Patients with active gallbladder disease
- Patients with any ongoing or planned anti-neoplastic or interferon therapy
- Poorly controlled diabetes mellitus
- Female patients who are pregnant or lactating, or are of childbearing potential and
not practicing a medically acceptable method of birth control
Other protocol-defined inclusion/exclusion criteria may apply.
We found this trial at
7
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials